CLINICAL TRIALS PROFILE FOR TRAZODONE HYDROCHLORIDE
✉ Email this page to a colleague
All Clinical Trials for Trazodone Hydrochloride
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00000179 ↗ | Agitation in Alzheimer's Disease | Completed | National Institute on Aging (NIA) | Phase 3 | 1969-12-31 | Agitation affects 70 to 90 percent of patients with AD. Signs of agitation include verbal and physical aggressiveness, irritability, wandering, and restlessness. These behaviors often make caring for patients at home very difficult. Trazodone and haldol are two of the most commonly prescribed drugs for agitation in AD patients. Behavior management, a non drug approach, has been effective in reducing signs of agitation. Researchers have yet to compare the effectiveness of drug versus non drug therapy to treat agitation in AD patients and determine which is the best treatment. The Alzheimer's Disease Cooperative Study, with funding from the National Institute on Aging, is conducting an agitation treatment program at 21 sites in 16 States. This study will assess which of the above treatments is most effective. |
| NCT00027053 ↗ | Trazodone for Sleep Disturbance in Early Alcohol Recovery | Completed | National Institute on Alcohol Abuse and Alcoholism (NIAAA) | Phase 2 | 2002-06-01 | This study is a randomized, double-blind clinical trial comparing trazodone (Desyrel) and placebo among sleep-disturbed, alcohol-dependent individuals shortly after discharge from an inpatient detoxification program. Subjects will undergo a baseline assessment and random assignment to trazodone or identical placebo for 12 weeks. All persons completing the alcohol detoxification at Stanley Street Treatment and Resources (SSTAR) will be screened. (SSTAR of Rhode Island provides detoxification services to non/underinsured persons of Rhode Island.) |
| NCT00027053 ↗ | Trazodone for Sleep Disturbance in Early Alcohol Recovery | Completed | Rhode Island Hospital | Phase 2 | 2002-06-01 | This study is a randomized, double-blind clinical trial comparing trazodone (Desyrel) and placebo among sleep-disturbed, alcohol-dependent individuals shortly after discharge from an inpatient detoxification program. Subjects will undergo a baseline assessment and random assignment to trazodone or identical placebo for 12 weeks. All persons completing the alcohol detoxification at Stanley Street Treatment and Resources (SSTAR) will be screened. (SSTAR of Rhode Island provides detoxification services to non/underinsured persons of Rhode Island.) |
| NCT00253890 ↗ | Insomnia and Drug Relapse Risk | Completed | National Institute on Drug Abuse (NIDA) | Phase 3 | 2005-10-01 | The purposes of this study are: 1. to evaluate the relationship between subjective complaints of sleep and objective measures of sleep quality, as measured through polysomnography, and 2. to evaluate the efficacy of trazodone, as compared to placebo, in individuals early in methadone maintenance. |
| NCT00253890 ↗ | Insomnia and Drug Relapse Risk | Completed | Butler Hospital | Phase 3 | 2005-10-01 | The purposes of this study are: 1. to evaluate the relationship between subjective complaints of sleep and objective measures of sleep quality, as measured through polysomnography, and 2. to evaluate the efficacy of trazodone, as compared to placebo, in individuals early in methadone maintenance. |
| NCT00270959 ↗ | Patient-Centered Collaborative Care for Preventing Post-Traumatic Stress Disorder After Traumatic Injury | Completed | National Institute of Mental Health (NIMH) | Phase 1 | 2006-06-01 | This study will evaluate the effectiveness of patient-centered collaborative care that combines behavioral therapy and drug therapy as compared to usual care in reducing symptoms of post-traumatic stress disorder in people who have survived a traumatic injury. |
| NCT00270959 ↗ | Patient-Centered Collaborative Care for Preventing Post-Traumatic Stress Disorder After Traumatic Injury | Completed | University of Washington | Phase 1 | 2006-06-01 | This study will evaluate the effectiveness of patient-centered collaborative care that combines behavioral therapy and drug therapy as compared to usual care in reducing symptoms of post-traumatic stress disorder in people who have survived a traumatic injury. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for Trazodone Hydrochloride
Condition Name
Clinical Trial Locations for Trazodone Hydrochloride
Trials by Country
Clinical Trial Progress for Trazodone Hydrochloride
Clinical Trial Phase
Clinical Trial Sponsors for Trazodone Hydrochloride
Sponsor Name
